Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New research indicates that in a mouse model of Parkinson disease, α-synuclein is trafficked from the brain to the gut by CD11c-expressing macrophages.
New guidelines for designing controlled clinical trials for idiopathic intracranial hypertension (IIH) have been published. The design of such trials remains a challenge, as the heterogeneity of IIH necessitates different outcome measures for specific clinical presentations.
A new study indicates that African American people with multiple sclerosis have higher markers of humoral disease pathology than white people with multiple sclerosis. However, apparent differences in pathophysiology between ethnic groups cannot be fully interpreted without more comprehensive studies that examine the effects of social inequality on disease.
Clinical boundaries between neurology and psychiatry hamper understanding of disorders with phenotypes that span these disciplines. In this Review, Peall et al. discuss rare genetic brain disorders with neurological and psychiatric phenotypes, and consider common underlying mechanisms that could be therapeutic targets.
Schizophrenia is a leading cause of global disability but lacks therapies that target all aspects of the disease. This Review summarizes our current understanding of the pathophysiological mechanisms underlying the disease, highlighting potential targets for new drug development.
Huntington disease (HD)-like 2 (HDL2) is a rare HD phenocopy that seems to be confined to people with African ancestry. This Review summarizes our current knowledge of HDL2 and highlights the need for further studies of neurodegenerative diseases on the African continent.
This Perspective proposes a tripartite model involving the amygdala, hippocampus and striatum as key structures underlying cognitive dysfunction in Parkinson disease. The authors explore the anatomical and functional relationships of the structures and summarize evidence of their involvement in the cognitive aspects of the disease.
